Published in Eur J Clin Pharmacol on August 01, 1979
Pharmacokinetics of phosphomycin during haemofiltration. Br J Clin Pharmacol (1984) 0.75
BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG) Ann Oncol (1999) 1.62
Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist (2001) 1.42
Gerontogenes mediate health and longevity in nematodes through increasing resistance to environmental toxins and stressors. Exp Gerontol (2000) 1.28
Pharmacokinetics of cefmetazole administered intramuscularly and intravenously to healthy adults. Antimicrob Agents Chemother (1985) 1.10
Concentrations of cefmetazole in plasma and tissue resulting from peri-incisional administration before appendectomy. Antimicrob Agents Chemother (1984) 1.02
Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer (2000) 1.00
Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother (1999) 0.94
The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid. Eur J Clin Pharmacol (1983) 0.92
Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol (1995) 0.90
Iron metabolism and fungal infections in patients with haematological malignancies. J Clin Pathol (1995) 0.90
Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. J Clin Pharm Ther (2005) 0.90
Growing teratoma syndrome: experience of a single institution. Eur Urol (1997) 0.90
Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients. Br J Cancer (1996) 0.87
High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. J Chromatogr B Biomed Sci Appl (1999) 0.87
Cimetidine and eosinophilic fasciitis. Ann Intern Med (1983) 0.86
Spinal metastatic disease: analysis of factors determining functional prognosis and the choice of treatment. Neurosurgery (1984) 0.86
Monitoring of serum levels of imipramine and desipramine and individualization of dose in enuretic children. Ther Drug Monit (1984) 0.86
Influence of dosage form and administration route on the pharmacokinetic parameters of cefadroxil. Int J Clin Pharmacol Ther Toxicol (1982) 0.85
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer (2000) 0.85
Comparison of two techniques (flow cytometry and alkaline immunophosphatase) in the evaluation of alveolar macrophage immunophenotype. Diagn Cytopathol (1993) 0.85
Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (1999) 0.85
Pharmacokinetics of cefoxitin in patients with normal or impaired renal function. Eur J Clin Pharmacol (1979) 0.84
Pharmacokinetics of cefoxitin in patients undergoing hemodialysis. Int J Clin Pharmacol Biopharm (1979) 0.84
Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Ann Oncol (1997) 0.83
Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit (1992) 0.82
Population pharmacokinetics of albendazole in patients with neurocysticercosis. Int J Clin Pharmacol Ther (2009) 0.82
Pharmacokinetics of cefoxitin during haemofiltration. Eur J Clin Pharmacol (1983) 0.82
Pharmacokinetics of cefamandole in patients undergoing hemodialysis. Int J Clin Pharmacol Biopharm (1979) 0.82
Pleural fluid levels of cefoxitin in patients with renal impairment. Int J Clin Pharmacol Ther Toxicol (1986) 0.82
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. Br J Cancer (2012) 0.81
Linearity of the pharmacokinetics of phosphomycin in serum and interstitial tissue fluid in rabbits. Arzneimittelforschung (1986) 0.81
Influence of pharmacokinetic model on vancomycin peak concentration targets. Ther Drug Monit (1996) 0.81
Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation. Transplant Proc (2009) 0.81
Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function. Eur J Drug Metab Pharmacokinet (1985) 0.81
Population pharmacokinetics of caffeine in premature neonates. Eur J Clin Pharmacol (1997) 0.81
Pharmacokinetics of rectal ketamine in children. Br J Anaesth (1989) 0.81
Disposition of cefoxitin in patients with pleural effusion. Clin Ther (1981) 0.81
Plasma renin activity, plasma aldosterone and distal urinary acidification in diabetics with chronic renal failure. Proc Eur Dial Transplant Assoc Eur Ren Assoc (1985) 0.80
Influence of dose in the urinary excretion of amikacin. Int J Clin Pharmacol Ther Toxicol (1984) 0.80
A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res Treat (1995) 0.80
Hypokalemia in opiate overdose. Clin Investig (1994) 0.80
Population pharmacokinetics of digoxin in pediatric patients. Ther Drug Monit (2002) 0.79
Comparison of methods of carbamazepine dosage, individualization in epileptic patients. J Clin Pharm Ther (1988) 0.79
[A 48-year-old male with renal infarction and thrombophilia]. Nefrologia (2008) 0.79
Disposition of cefoxitin in the elderly. Int J Clin Pharmacol Ther Toxicol (1980) 0.79
Influence of dose on the pharmacokinetics of cefadroxil. Eur J Clin Pharmacol (1980) 0.79
Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol (1998) 0.78
Disposition of cefoxitin in patients with ascites. Eur J Clin Pharmacol (1981) 0.78
Modification in the pharmacokinetics of amikacin during development. Eur J Clin Pharmacol (1982) 0.77
Serum glycosidases in diabetes mellitus in relation to the retinopathy and to the length of the disease. Clin Chim Acta (1983) 0.77
Non-linear tissue binding of amikacin in rats: the effect of renal impairment. Eur J Drug Metab Pharmacokinet (1988) 0.77
Digoxin pharmacokinetics in patients with high serum digoxin concentrations. J Clin Pharm Ther (1993) 0.77
Predictive performance of two phenytoin pharmacokinetic dosing programs from nonsteady state data. Ther Drug Monit (1994) 0.77
Pharmacokinetics of amikacin in intensive care unit patients. J Clin Pharm Ther (1996) 0.77
Bayesian forecasting in paediatric populations. Clin Pharmacokinet (1996) 0.77
Urinary iron excretion in patients with chronic obstructive airways disease (COAD). Ann Clin Biochem (1995) 0.76
Pharmacokinetics of amikacin in children with normal and impaired renal function. Kidney Int (1981) 0.76
Pharmacokinetics of cefazolin administered as a new drug delivery system in healthy volunteers. Biopharm Drug Dispos (1989) 0.76
The biotransformation kinetics of ketamine "in vitro" in rabbit liver and lung microsome fractions. Eur J Drug Metab Pharmacokinet (1986) 0.76
Antigen phenotype and cytotoxic activity of natural killer cells in hemodialysis patients. Am J Kidney Dis (1996) 0.76
Urinary prostaglandins (PGE2 and PGI2) in hyporeninaemic hypoaldosteronism in diabetic patients with chronic renal failure. Nephrol Dial Transplant (1994) 0.76
[Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Nefrologia (2003) 0.76
[Interferon-alpha and its deleterious effects on kidney transplant: regarding one case]. Nefrologia (2009) 0.76
The pharmacokinetics of cefadroxil associated with probenecid. Int J Clin Pharmacol Ther Toxicol (1981) 0.76
Individualization of theophylline dosage in adults with bronchial asthma. Drug Intell Clin Pharm (1986) 0.76
False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer (1993) 0.76
Effect of experimentally induced renal impairment on the pharmacokinetics of cefadroxil in rabbits. Arzneimittelforschung (1981) 0.75
The influence of ascites on the pharmacokinetics of amikacin. Int J Clin Pharmacol Ther Toxicol (1980) 0.75
Autonomic nervous system in haemodialysis. Nephrol Dial Transplant (1988) 0.75
[Sudden death, exercise, and blood potassium]. Med Clin (Barc) (1993) 0.75
Pharmacokinetics of phosphomycin during haemofiltration. Br J Clin Pharmacol (1984) 0.75
Population pharmacokinetics of high dose ibuprofen in cystic fibrosis. Arch Dis Child (2003) 0.75
Phosphomycin levels in serum and interstitial tissue fluid in a multiple dosage regimen in rabbits. Arzneimittelforschung (1987) 0.75
[CEA, tumor marker of questioned utility in hemodialysis: report of a case]. Nefrologia (2007) 0.75
Ceforanide pharmacokinetics in haemodialysis: the effect of ultrafiltration. Biopharm Drug Dispos (1986) 0.75
[Intestinal absorption of vitamin B 12 in renal insufficiency]. Rev Clin Esp (1980) 0.75
Pharmacokinetics of cefotiam during hemofiltration. Int J Clin Pharmacol Ther Toxicol (1986) 0.75
[An infrequent cause of hypertriglyceridemia in kidney transplantation]. Nefrologia (2008) 0.75
Focal segmental glomerular sclerosis in three generations of a single family. Int J Pediatr Nephrol (1985) 0.75
[Late-onset hemothorax after left jugular vein catheterization for hemodialysis]. Nefrologia (2008) 0.75
[C-reactive protein, acute or intermediate phase reactant in peritoneal dialysis patients with peritonitis?]. Nefrologia (2007) 0.75